MX2019008994A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). - Google Patents

Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Info

Publication number
MX2019008994A
MX2019008994A MX2019008994A MX2019008994A MX2019008994A MX 2019008994 A MX2019008994 A MX 2019008994A MX 2019008994 A MX2019008994 A MX 2019008994A MX 2019008994 A MX2019008994 A MX 2019008994A MX 2019008994 A MX2019008994 A MX 2019008994A
Authority
MX
Mexico
Prior art keywords
ahr
aryl hydrocarbon
hydrocarbon receptor
modulator compounds
compounds
Prior art date
Application number
MX2019008994A
Other languages
English (en)
Inventor
Steeneck Christoph
Hoffmann Thomas
Deuschle Ulrich
Albers Michael
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of MX2019008994A publication Critical patent/MX2019008994A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.
MX2019008994A 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr). MX2019008994A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000158 2017-02-01
PCT/EP2018/052542 WO2018141857A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
MX2019008994A true MX2019008994A (es) 2019-12-19

Family

ID=57960223

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008994A MX2019008994A (es) 2017-02-01 2018-02-01 Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).

Country Status (28)

Country Link
US (1) US10981908B2 (es)
EP (1) EP3577112B1 (es)
JP (1) JP6849823B2 (es)
KR (1) KR102320516B1 (es)
CN (1) CN110248940B (es)
AR (1) AR110789A1 (es)
AU (1) AU2018216957B2 (es)
BR (1) BR112019015716A2 (es)
CA (1) CA3050827C (es)
CL (1) CL2019002108A1 (es)
CO (1) CO2019007881A2 (es)
CR (1) CR20190392A (es)
CU (1) CU20190069A7 (es)
EA (1) EA038318B1 (es)
EC (1) ECSP19055169A (es)
ES (1) ES2858329T3 (es)
IL (1) IL268080B (es)
MX (1) MX2019008994A (es)
MY (1) MY196831A (es)
NI (1) NI201900076A (es)
PE (1) PE20191478A1 (es)
PH (1) PH12019550135A1 (es)
SG (1) SG11201906958TA (es)
TW (1) TWI752155B (es)
UA (1) UA122745C2 (es)
UY (1) UY37589A (es)
WO (1) WO2018141857A1 (es)
ZA (1) ZA201904771B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
JP7382348B2 (ja) 2018-02-06 2023-11-16 アイディアヤ バイオサイエンシーズ，インコーポレイティド ＡｈＲモジュレータ
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
SG11202105213XA (en) * 2018-11-30 2021-06-29 Celularity Inc Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
US20230108408A1 (en) * 2020-01-23 2023-04-06 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
AU2021226411A1 (en) 2020-02-26 2022-09-22 Jaguahr Therapeutics Pte Ltd Pyridopyrimidine derivatives useful in modulation of AhR signalling
US20230234967A1 (en) * 2020-05-28 2023-07-27 Senda Biosciences, Inc. Fused Azole Heterocycles as AHR Antagonists
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114835687B (zh) * 2021-04-02 2023-09-05 北京华森英诺生物科技有限公司 AhR抑制剂
CN115572282A (zh) * 2021-07-05 2023-01-06 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
WO2024076300A1 (en) 2022-10-03 2024-04-11 Jaguahr Therapeutics Pte Ltd Compounds useful in modulation of ahr signalling

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (en) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. 2-phenylindole derivative
ES2215242T3 (es) * 1996-11-19 2004-10-01 Amgen Inc. Agentes antiinflamatorios de pirrol condensado sustituido con arilo y heteroarilo.
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
ATE485294T1 (de) 2005-11-18 2010-11-15 Hoffmann La Roche Azaindol-2-carboxamid-derivate
US8563573B2 (en) * 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
CA2777565C (en) 2009-10-13 2019-06-18 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic diphenylamine small molecule compounds and their uses
EP2496081B1 (en) * 2009-11-02 2020-03-25 Ariagen, Inc. Ite for cancer intervention and eradication
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
CN102834393B (zh) 2010-02-03 2015-07-22 武田药品工业株式会社 细胞凋亡信号调节激酶1抑制剂
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
EP2598138B1 (en) 2010-07-27 2020-05-06 Trustees of Boston University Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
MX2015004500A (es) 2012-10-17 2015-07-06 Hoffmann La Roche Derivados de 6-aminoindol como antagonistas del canal receptor de potencial transitorio (trp).
CN105308036B (zh) 2012-12-21 2019-06-21 普莱希科公司 用于激酶调节的化合物和方法及其适应症
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
TWI752155B (zh) 2022-01-11
PH12019550135A1 (en) 2020-06-01
IL268080A (en) 2019-09-26
BR112019015716A2 (pt) 2020-03-24
CL2019002108A1 (es) 2019-12-20
ECSP19055169A (es) 2019-08-30
TW201831480A (zh) 2018-09-01
KR102320516B1 (ko) 2021-11-02
US10981908B2 (en) 2021-04-20
EP3577112A1 (en) 2019-12-11
MY196831A (en) 2023-05-03
CR20190392A (es) 2019-10-21
CU20190069A7 (es) 2020-03-04
IL268080B (en) 2022-03-01
ES2858329T3 (es) 2021-09-30
CN110248940B (zh) 2022-07-01
EA201991599A1 (ru) 2020-03-10
CN110248940A (zh) 2019-09-17
JP2020506228A (ja) 2020-02-27
WO2018141857A1 (en) 2018-08-09
UY37589A (es) 2018-02-28
UA122745C2 (uk) 2020-12-28
AU2018216957B2 (en) 2020-09-24
CO2019007881A2 (es) 2019-10-09
CA3050827C (en) 2021-09-07
EP3577112B1 (en) 2020-12-30
AR110789A1 (es) 2019-05-02
SG11201906958TA (en) 2019-08-27
NI201900076A (es) 2020-01-23
KR20190104410A (ko) 2019-09-09
CA3050827A1 (en) 2018-08-09
AU2018216957A1 (en) 2019-08-22
JP6849823B2 (ja) 2021-03-31
NZ755709A (en) 2021-04-30
PE20191478A1 (es) 2019-10-16
EA038318B1 (ru) 2021-08-09
US20190389857A1 (en) 2019-12-26
ZA201904771B (en) 2022-05-25

Similar Documents

Publication Publication Date Title
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
PH12019550135A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
PH12019550136A1 (en) ARYL HYDROCARBON RECEPTOR (AhR)MODULATOR COMPOUNDS
PH12020550523A1 (en) Modulators of the integrated stress pathway
PH12018502329A1 (en) Modulators of the integrated stress pathway
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
MX2017014375A (es) Moduladores del ccr2.
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
MD3319963T2 (ro) 4-Azaindoli substituiți și utilizarea lor în calitate de modulatori ai receptorului GluN2B
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
PH12016501393A1 (en) Substituted bicyclic heteroaryl compounds as rxr agonists
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
PH12017501601A1 (en) Use of isolated fractions of mastic gum for treating optic neuropathy
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
NZ765690A (en) Aryl receptor modulators and methods of making and using the same